Dabigatran 150mg was superior to warfarin and dabigatran 110mg was noninferior to warfarin for preventing stroke in patients with atrial fibrillation (AF) regardless of CHA2DS2-VASc scores, as shown by the results of a subgroup analysis of the RE-LY trial presented today at ACC.11, the American College of Cardiology’s 60th Annual Scientific Session.
Your search for Warfarin returned 3 results
Patients with newly diagnosed or previously treated multiple myeloma (MM) who receive thalidomide (T)- or lenalidomide (L)-based regimens are at high risk of venous thromboembolism (VTE), and it is uncertain whether thromboprophylaxis provides a clear benefit, especially in those who receive L-based therapy or have previously treated disease, according to results of a systematic review and meta-analysis that were shown at the 52nd American Society of Hematology Meeting and Exposition.
A prospective phase 2 study of the low-molecular-weight heparin (LMWH) tinzaparin for initial treatment and secondary prophylaxis of venous thromboembolism (VTE) associated with cancer treatment found the agent to be safe and efficacious, with the recurrent VTE event rate comparing favorably with that reported for another LMWH, dalteparin according to a study presented at the 52nd American Society of Hematology Meeting and Exposition.